Unravel Biosciences

Unravel Biosciences is a clinical-stage therapeutics company spun out of Harvard's Wyss Institute that starts with a patient's RNA rather than a drug target. Its BioNAV probabilistic network model of human health screens 40,000-plus compounds in silico - reporting roughly 200x the hit rate of conventional screens - to find existing molecules that can push a disease back toward health. The company validates predictions in engineered whole-organism models (including CRISPR-edited tadpoles) and then in patients, aiming to bring effective, lower-cost therapies to rare and overlooked diseases. Its lead asset, RVL-001 (a proprietary formulation of vorinostat), holds FDA Orphan Drug Designation for Rett syndrome and has entered clinical studies.